13-07-2012: Amakem NV announced the appointment of Maarten van Geffen as Head of CMC and Operations. Mr. van Geffen brings an exceptional track record in international management experience in pharmaceutical development to Amakem.
Mr. Maarten van Geffen’s career in the industry spans nearly 25 years, with substantial experience in pharmaceutical product development and regulatory affairs. Maarten was previously Director of Product Development at Shire-Movetis NV, where he was responsible for the pharmaceutical development of the GI early and late phase products and was the CMC lead for due diligence of early phase and late phase small and large molecule products. While at the Company, Maarten also played a pivotal role in the strategic development of commercial and pipeline products as well as carrying out quality control on dossiers and interacting with regulatory authorities.
Prior to working at Shire-Movetis NV, Mr. van Geffen held several positions as Director of CMC Regulatory Affairs at Barrier Therapeutic NV, Centocor BV, and Janssen Research Foundation, where he was involved in managing and executing product development and regulatory approval. Before initiating his career in the industry Mr. Van Geffen was assessor of quality part pharmaceutical dossiers for the Dutch Health and Environmental agency.
Mr. van Geffen received an MSc in Biology from the University of Utrecht, the Netherlands. He has also authored a number of publications on various topics.
Amakem NV announced the appointment of Maarten van Geffen as Head of CMC and Operations. Mr. van Geffen brings an exceptional track record in international management experience in pharmaceutical development to Amakem.Mr. Maarten van Geffen’s career in the industry spans nearly 25 years, wi ... more
Amakem NV announced the appointment of Dr. Steve Pakola as Chief Medical Officer and Dr. George Lasezkay to its Board as an Independent Director. Both have exceptional track records in the biotechnology industry and bring a wealth of ophthalmology experience to Amakem.Dr. Pakola was previou ... more
Amakem and Devgen announced the closure of a EUR 1.5 million seed financing round and the contribution in kind of certain assets, intellectual property and know-how of Devgen's former pharma division. The financing round was led by LRM, through its ARKIV subsidiary KMOFIN. Other investors ... more